TW200716151A - Polymeric derivative of cytidine metabolic antagonist - Google Patents

Polymeric derivative of cytidine metabolic antagonist

Info

Publication number
TW200716151A
TW200716151A TW095116441A TW95116441A TW200716151A TW 200716151 A TW200716151 A TW 200716151A TW 095116441 A TW095116441 A TW 095116441A TW 95116441 A TW95116441 A TW 95116441A TW 200716151 A TW200716151 A TW 200716151A
Authority
TW
Taiwan
Prior art keywords
metabolic antagonist
cytidine metabolic
cytidine
derivative
polymeric derivative
Prior art date
Application number
TW095116441A
Other languages
English (en)
Other versions
TWI371284B (zh
Inventor
Akira Masuda
Takeshi Onda
Hiroko Mashiba
Keiichirou Yamamoto
Kazutoshi Takashio
Original Assignee
Nippon Kayaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk filed Critical Nippon Kayaku Kk
Publication of TW200716151A publication Critical patent/TW200716151A/zh
Application granted granted Critical
Publication of TWI371284B publication Critical patent/TWI371284B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
TW095116441A 2005-05-11 2006-05-09 Polymeric derivative of cytidine metabolic antagonist TW200716151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005138249 2005-05-11

Publications (2)

Publication Number Publication Date
TW200716151A true TW200716151A (en) 2007-05-01
TWI371284B TWI371284B (zh) 2012-09-01

Family

ID=37396423

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095116441A TW200716151A (en) 2005-05-11 2006-05-09 Polymeric derivative of cytidine metabolic antagonist

Country Status (13)

Country Link
US (1) US7700709B2 (zh)
EP (1) EP1881020B1 (zh)
JP (1) JP5000512B2 (zh)
KR (1) KR101312417B1 (zh)
CN (1) CN101218280B (zh)
AU (1) AU2006245107B2 (zh)
BR (1) BRPI0609095A2 (zh)
CA (1) CA2606939C (zh)
DE (1) DE602006016103D1 (zh)
ES (1) ES2350258T3 (zh)
RU (1) RU2404980C2 (zh)
TW (1) TW200716151A (zh)
WO (1) WO2006120914A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495099B2 (en) * 2002-10-31 2009-02-24 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
WO2004082718A1 (ja) * 2003-03-20 2004-09-30 Nippon Kayaku Kabushiki Kaisha 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物
KR101203475B1 (ko) * 2004-09-22 2012-11-21 니폰 가야꾸 가부시끼가이샤 신규 블록 공중합체, 미셀 제제물 및 이를 유효성분으로함유하는 항암제
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
RU2009105670A (ru) * 2006-07-19 2010-08-27 Ниппон Каяку Кабусики Кайся (Jp) Высокомолекулярный конъюгат комбретастатинов
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
EP2080779B1 (en) * 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
ATE459659T1 (de) * 2006-11-07 2010-03-15 Dsm Ip Assets Bv Carbamat, thiocarbamat oder carbamid mit einer biomolekularen gruppierung
JP5548365B2 (ja) * 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
EP2258397B1 (en) * 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of physiologically active substance
WO2009136572A1 (ja) 2008-05-08 2009-11-12 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
CN102421827B (zh) 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
IT1401360B1 (it) * 2010-05-19 2013-07-18 Lembo Agenti anti-virali e relative composizioni
US8840875B2 (en) 2010-05-19 2014-09-23 Paolo Ferruti Anti-viral agents and compositions thereof
EP2641605B1 (en) 2010-11-17 2018-03-07 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolism antagonist
WO2012098557A1 (en) * 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
EP2754682B1 (en) 2011-09-11 2017-06-07 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
JP6223995B2 (ja) 2012-11-08 2017-11-01 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
JP2017160125A (ja) * 2014-08-04 2017-09-14 日本化薬株式会社 核酸代謝拮抗剤が結合したポリアミノ酸誘導体。
RU2732612C2 (ru) 2015-02-23 2020-09-21 Ниппон Каяку Кабусики Каися Блок-сополимерный конъюгат физиологически активного вещества
JP6851977B2 (ja) * 2015-11-18 2021-03-31 日本化薬株式会社 マクロライド系免疫抑制剤の高分子誘導体
EP3400945A4 (en) 2016-01-08 2019-09-11 Nippon Kayaku Kabushiki Kaisha POLYMER DERIVATIVE OF MACROLIDE IMMUNOSUP PRESSIVA
CN106117561B (zh) * 2016-06-27 2020-03-13 中国科学院长春应用化学研究所 一种吉西他滨衍生物及其制备方法
KR101906321B1 (ko) * 2016-07-06 2018-10-10 주식회사 삼양바이오팜 수난용성 약물을 포함하는 고분자 미셀 제제의 시험관 내 방출시험 및 평가 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097307A3 (en) * 1982-06-21 1985-01-09 American Hoechst Corporation Thermo-chemically cross-linked poly(p-methylstyrene) and process to obtain it
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
JP3310000B2 (ja) 1990-11-07 2002-07-29 靖久 桜井 水溶性高分子抗癌剤及び薬物担持用担体
JP3268913B2 (ja) * 1992-10-27 2002-03-25 日本化薬株式会社 高分子担体
US5571889A (en) * 1994-05-30 1996-11-05 Mitsui Toatsu Chemicals, Inc. Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same
JPH0848766A (ja) 1994-05-30 1996-02-20 Mitsui Toatsu Chem Inc 重合体及びその製造方法
JP2694923B2 (ja) 1995-08-21 1997-12-24 科学技術振興事業団 水溶性高分子化医薬製剤
JPH11279083A (ja) 1998-03-30 1999-10-12 Nippon Kayaku Co Ltd 可溶化剤
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
CA2437989A1 (en) * 2001-02-20 2002-08-29 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO2004084871A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
CN102172405B (zh) * 2003-09-17 2014-11-12 耐科塔医药公司 多支链聚合物的药物前体
JP4723380B2 (ja) * 2003-09-25 2011-07-13 テルモ株式会社 ポリエチレングリコール誘導体及びこれを膜構成成分とする薬物担体
SI1695991T1 (sl) * 2003-12-10 2010-04-30 Toudai Tlo Ltd Koordinacijski kompleks diaminocikloheksan platine (II) z blok kopolimerom, ki vsebuje segment poli(karboksilne kisline) in antitumorni agens, ki jih vsebuje

Also Published As

Publication number Publication date
EP1881020A4 (en) 2009-09-02
KR20080013883A (ko) 2008-02-13
RU2007145718A (ru) 2009-06-20
EP1881020A1 (en) 2008-01-23
EP1881020B1 (en) 2010-08-11
DE602006016103D1 (de) 2010-09-23
US7700709B2 (en) 2010-04-20
KR101312417B1 (ko) 2013-09-27
US20090012252A1 (en) 2009-01-08
AU2006245107A1 (en) 2006-11-16
JP5000512B2 (ja) 2012-08-15
BRPI0609095A2 (pt) 2010-02-17
TWI371284B (zh) 2012-09-01
ES2350258T3 (es) 2011-01-20
CA2606939A1 (en) 2006-11-16
JPWO2006120914A1 (ja) 2008-12-18
CA2606939C (en) 2013-09-03
CN101218280B (zh) 2012-06-27
AU2006245107B2 (en) 2011-02-10
CN101218280A (zh) 2008-07-09
WO2006120914A1 (ja) 2006-11-16
RU2404980C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
TW200716151A (en) Polymeric derivative of cytidine metabolic antagonist
JO3492B1 (ar) تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط nep
NZ588839A (en) Multivalent vla-4 antagonists comprising polyethylene glycol moieties
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL197924A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
IN2012DN02609A (zh)
WO2007005941A3 (en) Liver targeted conjugates
MX2009007145A (es) Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
ATE414725T1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
WO2004084950A3 (en) Cell targeting methods and compositions
IL189781A0 (en) Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
PL1876169T3 (pl) Pochodne amin n-acylowych i aminokwasów zawierające fenyl, sposoby ich wytwarzania, kompozycje farmaceutyczne i ich zastosowanie
TW200735660A (en) Camera mount
IL200847A0 (en) Oligomer-antihistamine inhibitor conjugates, compositions comprising the same and uses thereof
TW200735875A (en) Pharmaceutical compositions
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
EA200870148A1 (ru) Производные сулиндака, их применение и получение
MX2010004110A (es) Formulacion para mejorar la funcion gastrointestinal.
EP1884510A4 (en) N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees